China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of a financing round, securing close to USD 210 million with backing from Temasek, Highlight Capital (HLC), and True Light. The Viva Biotech Holdings group obtained nearly USD 150 million through the transfer of approximately 24.21% equity in its CRO business entity, Viva Biotech (Shanghai) Ltd. This follows previous convertible bond financing of approximately USD 60 million, which will be automatically converted into shares at the price of HKD 2.0 per share on the delivery date.
VIVA Biotech’s Comprehensive Drug Discovery Services
Founded in 2008, Viva Biotech provides a one-stop service range from early-stage structure-based drug R&D to commercial drug delivery for global biopharmaceutical innovators. The company leads in early-stage to late-phase drug discovery expertise by integrating a dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, ASMS, SPR, HDX, CADD, and more. With a global reach, Viva Biotech has attracted 2189 clients and incubated 0.92 biomedicine startups.- Flcube.com
